Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Return on Equity (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Return on Equity for 11 consecutive years, with 0.24% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity fell 7.0% year-over-year to 0.24%, compared with a TTM value of 0.24% through Sep 2025, down 7.0%, and an annual FY2024 reading of 0.23%, down 2.0% over the prior year.
  • Return on Equity was 0.24% for Q3 2025 at Sunshine Biopharma, up from 0.26% in the prior quarter.
  • Across five years, Return on Equity topped out at 25.85% in Q4 2021 and bottomed at 1.33% in Q1 2023.
  • Average Return on Equity over 5 years is 2.44%, with a median of 0.21% recorded in 2023.
  • The sharpest move saw Return on Equity soared 606bps in 2021, then plummeted -2671bps in 2022.
  • Year by year, Return on Equity stood at 25.85% in 2021, then tumbled by -103bps to 0.86% in 2022, then soared by 76bps to 0.21% in 2023, then decreased by -1bps to 0.21% in 2024, then dropped by -14bps to 0.24% in 2025.
  • Business Quant data shows Return on Equity for SBFM at 0.24% in Q3 2025, 0.26% in Q2 2025, and 0.22% in Q1 2025.